A detailed history of Rise Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rise Advisors, LLC holds 352 shares of NBIX stock, worth $44,228. This represents 0.02% of its overall portfolio holdings.

Number of Shares
352
Previous 352 -0.0%
Holding current value
$44,228
Previous $48,000 16.67%
% of portfolio
0.02%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 09, 2024

BUY
$130.4 - $143.74 $39,120 - $43,122
300 Added 576.92%
352 $48,000
Q3 2023

Oct 10, 2023

SELL
$94.02 - $117.1 $2,068 - $2,576
-22 Reduced 29.73%
52 $5,000
Q2 2023

Jul 10, 2023

SELL
$89.53 - $104.87 $179 - $209
-2 Reduced 2.63%
74 $6,000
Q1 2023

Apr 05, 2023

BUY
$94.11 - $123.02 $188 - $246
2 Added 2.7%
76 $7,000
Q1 2022

Apr 22, 2022

BUY
$72.45 - $94.81 $1,521 - $1,991
21 Added 39.62%
74 $7,000
Q4 2021

Feb 24, 2022

BUY
$79.65 - $106.22 $4,221 - $5,629
53 New
53 $4.51 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Rise Advisors, LLC Portfolio

Follow Rise Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rise Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rise Advisors, LLC with notifications on news.